Skip to main content
SpringerLink
Log in

Minimal Residual Disease in Head and Neck Cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) is a complex disease. Patients with more advanced stages are treated with curative intent by a combination of surgery and radiotherapy, but still about 50% develop a relapse: locally, regionally and at distant sites. This clinical outcome strongly indicates that small histologically undetectable tumor deposits remain at these sites: ‘minimal residual disease’. In this article the different aspects related to minimal residual head and neck cancer will be reviewed shortly. The management of patients with head and neck cancer as well as the clinical problems in diagnosis and treatment will be described. The crucial role of minimal residual disease in head and neck cancer will be defined and diagnostic approaches to address the problem will be reviewed. We argue that the infiltration and dissemination of HNSCC takes place beyond the level of histopathological detection, and further that molecular staging will at least in part fill in the gap between anatomical TNM staging and the clinical outcome. However, it is not only the presence of infiltrated or disseminated tumor cells that will determine the prognosis. Also the biological characteristics of the tumor cells at the various sites are important for the clinical follow-up. Promising therapeutic approaches to deal with minimal residual disease will be discussed shortly. Finally the issues ‘field cancerization’ and second primary tumors in head and neck cancer are addressed as these are closely linked to local recurrence and distant metastases. Moreover, second primary tumors will gain more importance when the primary disease and the frequency of relapses are better controlled.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T: Cancer statistics, 1992. CA Cancer J Clin. 42: 19–38, 1992

    Google Scholar 

  2. Howaldt HP, Kainz M: Projektbericht des Zentralregisters der Deutsch-Österreichisch-Schweizerischen Arbeiteitskreises für Tumoren im Kiefer-und Gesichtsbereich November 1997

  3. Franceschi D, Gupta R, Spiro RH, Shah JP: Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 166: 360–365, 1993

    Google Scholar 

  4. Zarbo RJ, Crissman JD: The surgical pathology of head and neck cancer. Semin Oncol 15: 10–19, 1988

    Google Scholar 

  5. Alvi A, Johnson JT: Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head and Neck 19: 500–505, 1997

    Google Scholar 

  6. Vikram B: Changing patterns of failure in advanced head and neck cancer. Arch-Otolaryngol 110: 564–565, 1984

    Google Scholar 

  7. Hannahs KJ, Hooper JA, Sigler A: Nursing care of the head and neck cancer patient. In: Suen JY, Myers EN (eds) Cancer of the Head and Neck. Churchill Livingstone, New York, 1981 pp 839

    Google Scholar 

  8. Callery CD, Spiro RH, Strong EW: Changing trends in the management of squamous carcinoma of the tongue. Am J Surg 148: 449–454, 1984

    Google Scholar 

  9. Crile G: Excision of cancer of the head and neck — with special reference to the plan of dissection based on one hundred and thirty-two operations. J Am Med Assoc 47: 1780–1787, 1906

    Google Scholar 

  10. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck. N Engl J Med 338: 1798–1804, 1998

    Google Scholar 

  11. Goepfert H: Are we making any progress? Arch Otolaryngol 110: 562–563, 1984; McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck: Arch Otolaryngol Head Neck Surg 121: 278–282, 1995

    Google Scholar 

  12. Petruzzelli GJ, Benefield J, Yong S: Mechanism of lymph node metastases: current concepts. Otolaryngol Clin North Am 31: 585–599, 1998

    Google Scholar 

  13. Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler Rl: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73–03. Int J Rad Oncol 20: 21–28, 1991

    Google Scholar 

  14. Vokes EE, Weichselbaum RR, Lippman SM, Hong KW: Medical progress; head and neck cancer; N Eng J Med 328: 184–194, 1993

    Google Scholar 

  15. Zelefsky MJ, Raben A, Strong EW, et al.: Long term results of postoperative radiotherapy for squamous cell cancers of the head and neck (abstract 289). Proceedings of the fourth International Conference on head and neck cancer, July 1996, Toronto

  16. Fisher B, Fisher ER: Barrier function of lymph node to tumor cells and erythrocytes; I Normal nodes; II Effect of X-Ray/inflammation/sensitization and tumor growth. Cancer 20: 1907–1919, 1967

    Google Scholar 

  17. Jones AS, Roland NJ, Field JK, Phillips DE: The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol 19: 63–69, 1994

    Google Scholar 

  18. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AAM: Prognostic factors of neck node metastasis. Clin Otolaryngol 7: 185–192, 1982

    Google Scholar 

  19. Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB: Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71: 452–456, 1993

    Google Scholar 

  20. Violaris NS, O'Neil D, Helliwell TR, Caslin AW, Roland NJ, Jones AS: Soft tissue cervical metastases of squamous carcinoma of the head and neck. Clin Otolaryngol 19: 394–399, 1993

    Google Scholar 

  21. Mendelson BC, Woods JE, Beahrs OH: Neck dissection in the treatment of carcinoma of the anterior two-thirds of the tongue. Surg Gynal Obstet 143: 75–80, 1976

    Google Scholar 

  22. Krause CJ, Lee JG, McCabe BF: Carcinoma of the oral cavity. Arch Otolaryngol 97: 354–358, 1973

    Google Scholar 

  23. Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446–1449, 1972

    Google Scholar 

  24. Shah JP, Candela FC, Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer 66: 109–113, 1990

    Google Scholar 

  25. Shah JP: Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160: 405–409, 1990

    Google Scholar 

  26. Candela FC, Kothari K, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head & Neck 12: 197–203, 1990

    Google Scholar 

  27. Candela FC, Shah J, Jaques DP, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg 4: 432–435, 1990

    Google Scholar 

  28. Bataini JP, Bernier J, Brugere J, Jaulerry Ch, Picco Ch, Brunin F: Natural history of neck disease in patients with squamous cell carcinoma of oropharynx and pharyngolarynx. Radiother Oncol 3: 245–255, 1985

    Google Scholar 

  29. Lindberg RD: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446–1449, 1972

    Google Scholar 

  30. Kinsey DL, James AG, Bonta JA: A study of metastatic carcinoma of the neck. Ann Surg 147: 366–374, 1958

    Google Scholar 

  31. Byers RM, Wolf PF, Ballantyne AJ: Rationale for elective modified neck dissection. Head Neck Surg 3: 160–167, 1988

    Google Scholar 

  32. Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P: Frequency and therapeutic implications of ‘skip metastases’ in the neck from squamous carcinoma of the oral tongue. Head & Neck 19: 14–19, 1997

    Google Scholar 

  33. Dennington ML, Carter DR, Meijers AD: Distant metastases in head and neck carcinoma. Laryngoscope 90: 196–201, 1980

    Google Scholar 

  34. Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M: Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch Otolaryngol Head Neck Surg 119: 65–68, 1993

    Google Scholar 

  35. Zbären P, Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113: 762–764, 1987

    Google Scholar 

  36. Spiro RH: The management of neck nodes in head and neck cancer: a surgeon's view. Bull NY Acad Med 61: 629–637, 1985

    Google Scholar 

  37. Vernham GA, Crowther JA: Head and neck carcinoma — stage at presentation. Clin Otolaryngol 19: 120–124, 1994

    Google Scholar 

  38. McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck. Arch Otolaryngol Head Neck Surg 121: 278–282, 1995

    Google Scholar 

  39. Yuen AP, Wie WI, Wong YM, Tang KC: Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck 19: 583–588, 1997

    Google Scholar 

  40. Van den Brekel MWM, Castelijns JA, Snow GB: Detection of lymph node metastases in the neck: radiologic criteria. Radiology 192: 617–618, 1994

    Google Scholar 

  41. Som PM: Detection of metastasis in cervical lymph nodes: CT and MRD criteria and differential diagnosis. Am J Rad 158: 961–969, 1992

    Google Scholar 

  42. Don DM, Anzai Y, Lufkin RB, Fu Y, Calcaterra TC: Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105: 669–674, 1995

    Google Scholar 

  43. Van den Brekel MWM, Castelijns JA, Snow GB: The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: How reliable is it. Am J Neuroradiol 19: 2191–2197, 1998

    Google Scholar 

  44. Bier J: Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Rec Res Cancer Res 134: 57–62, 1994

    Google Scholar 

  45. Van den Brekel MWM, Castelijns JA, Stel HV, Luth WJ, Valk J, van der Waal I, Snow GB: Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology 180: 457–461, 1991

    Google Scholar 

  46. McIvor NP, Freeman JL, Salem S, Elden L, Noyek AM, Bedard YC: Ultrasonography and ultrasound-guided fine-needle aspiration biopsy of head and neck lesions: a surgical perspective. Laryngoscope 104: 669–674, 1994

    Google Scholar 

  47. Van den Brekel MWM, Castelijns JA, Stel HV, Golding RP, Meyer CJ, Snow GB: Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol 250: 11–17, 1993

    Google Scholar 

  48. Strong EW: How does the site and the stage of the primary and ist therapy influence the treatment of the patient with the N0 neck? Proceedings of the Fourth International Conference on Head and Neck Cancer Vol IV: 548–556, 1996

    Google Scholar 

  49. Loree TR, Strong EW: Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160: 410–414, 1990

    Google Scholar 

  50. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429–435, 1995

    Google Scholar 

  51. Davidson TM, Nahum AM, Astarita RW: Microscopic controlled excisions for epidermoid carcinoma of the head and neck. Otolaryngol, Head Neck Surg 89: 244–251, 1981

    Google Scholar 

  52. Davidson TM, Haghighi P, Baird S, Astarita RW, Seagren S: MOHS for head and neck mucosal cancer: report on 111 patients. Laryngoscope 98: 1078–1083, 1988

    Google Scholar 

  53. Davidson TM, Nahum AM, Haghighi P, Astarita RW, Saltzstein SL, Seagren S: The biology of head and neck cancer: detection and control by parallel histologic sections. Arch Otolaryngol 110: 193–196, 84

  54. Rouviere H: Anantomy of the Human Lymphatic System. Ann Arbor: Edwards Brothers, 1938

    Google Scholar 

  55. Fisch UP, Sigel ME: Cervical lymphatic system as visualized by lymphography. Ann Otol 73: 869–883, 1964

    Google Scholar 

  56. Huang XZ, Wu JF, Spong S, Sheppard D: The integrin alpha-v-beta-6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci 111: 2189–2195, 1998

    Google Scholar 

  57. Pilcher BK, Dumin JA, Sudbeck BD. Krane SM, Welgus HG, Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137: 1445–1457, 1997

    Google Scholar 

  58. van den Brekel MWM, Stel HV, Valk P, van der Waal I, Meyer CJLM, Snow GB: Micrometastases from squamous cell carcinoma in neck dissection specimens. Eur Arch Otorhinolaryngol 249: 349–353, 1992

    Google Scholar 

  59. Voit C, Schoengen A, Peter RU: Increased sensitivity in early detection of submicroscopic lymph node metastases in melanoma patients. Brit J Cancer 77Suppl 1: 29, 1998

    Google Scholar 

  60. Pantel K: Detection of minimal disease in patients with solid tumors. J Hematother 5: 359–367, 1996

    Google Scholar 

  61. Pantel K, Braun S, Passlick B, Schlimok G: minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Progr. Histochem. Cytochem 30: 1–61, 1996

    Google Scholar 

  62. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti–17–1A monoclonal antibodies. Proc Natl Acad Sci 84: 8672–8676, 1987

    Google Scholar 

  63. Pantel K, Izbicki J, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649–653, 1996

    Google Scholar 

  64. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller, G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer. Lancet 340: 685–689, 1992

    Google Scholar 

  65. Gath HJ, Heissler E, Hell B, Bier J, Riethmuller G, Pantel K: Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg 24: 351–355, 1995

    Google Scholar 

  66. Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E: Mikromettasen im knockenmark von patienten mit karzinomen des kopf-hals-bereiches. Laryngo Rhino Otol 73: 88–93, 1994

    Google Scholar 

  67. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15: 2701–2708, 1997

    Google Scholar 

  68. Dingemans A-MC, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin 19 transcripts by reverse transcriptase polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest 77: 213–220, 1997

    Google Scholar 

  69. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488–2492, 1996

    Google Scholar 

  70. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marschall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706–709, 1991

    Google Scholar 

  71. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91: 9871–9875, 1994

    Google Scholar 

  72. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278: 1054–1059, 1997

    Google Scholar 

  73. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621–624, 1997

    Google Scholar 

  74. Traweek ST, Liu J, Battifora H: Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. Am J Pathol 142: 1111–1118, 1993

    Google Scholar 

  75. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K: Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Eng J Med 337: 1188–1194, 1997

    Google Scholar 

  76. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Eng J Med 339: 223–228, 1998

    Google Scholar 

  77. Hynes RO: Integrins: versality, modulation, and signalling in cell adhesion. Cell 69: 11–25, 1992

    Google Scholar 

  78. Jones PH, Harper S, Watt FM: Stem cell patterning and fate in human epidermis. Cell 80: 83–93, 1995

    Google Scholar 

  79. Watt FM, Jones PH: Expression and function of the keratinocyte integrins. Development Suppl: 185–192, 1993

    Google Scholar 

  80. Jones PH, Watt FM: Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73: 713–724, 1993

    Google Scholar 

  81. Wolf GT, Carey TE, Schmaltz SP, McClatchey KD, Poore J, Glaser L, Hayashida DJ, Hsu S: Altered antigen expression predicts outcome in squamous cell carcinoma of the head and neck. J Nat Cancer Inst 82: 1566–1572, 1990

    Google Scholar 

  82. Jones J, Watt FM, Speight PM: Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26: 63–68, 1997

    Google Scholar 

  83. Thomas GJ, Jones J, Speight PM: Integrins and oral cancer. Oral Oncol 33: 381–388, 1997

    Google Scholar 

  84. Zhang K, Kim, JP, Woodley DT, Waleh NS, Chen YQ, Kramer RH: Restricted expression and function of laminin 1-binding integrins in normal and malignant oral mucosal keratinocytes. Cell-Adhes-Commun 4: 159–174, 1996

    Google Scholar 

  85. Cortesina G, Bussi M, Carlevato MT, Ferro S, Panizzut B, Cavalot AL, Gervasio CF, Marchisio PC: Significance of adhesion molecules as biological prognostic factor in locally advanced laryngeal squamous cell carcinomas. Acta Otolaryngol Stockh 116: 350–352, 1996

    Google Scholar 

  86. Vassalli JD, Saurat JH: Cuts and scrapes? Plasmin heals. Nature Med 2: 284–285, 1996

    Google Scholar 

  87. Reinartz J, Schaefer B, Bechtel MJ, Kramer MD: Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 223: 91–101, 1996

    Google Scholar 

  88. Kramer MD, Schaefer B, Reinartz J: Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe-Seyler 376: 131–141, 1995

    Google Scholar 

  89. Boyd D: Invasion and metastasis, Cancer Metas Rev 15: 77–89, 1996

    Google Scholar 

  90. Schmitt M, Janicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 4 Suppl: 3–26, 1992

    Google Scholar 

  91. Parolini S, Flagiello D, Cinquetti A, Gozzi R, Cristini S, Cappiello J, Nicolai P, Rusnati M, Presta M, Tosatti MM: Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 74: 1168–1174, 1996

    Google Scholar 

  92. Kook YH, Adamski J, Zelent A, Ossowski L: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983–3991, 1994

    Google Scholar 

  93. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM, Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 67: 333–338, 1996

    Google Scholar 

  94. Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: opportunities for new therapeutic approaches. Nature Med 3: 505–509, 1997

    Google Scholar 

  95. Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8: 838–847, 1990

    Google Scholar 

  96. Schuller DE, Metch B, Mattox D, McCracken JD: Prospective chemotherapy in advanced head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98: 1205–1211, 1988

    Google Scholar 

  97. Laramore GE, Scott CB, al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol 23: 705–713, 1992

    Google Scholar 

  98. Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol 19: 1347–1350, 1990

    Google Scholar 

  99. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12: 2648–2653, 1994

    Google Scholar 

  100. Merlano M, Corvo R, Margarino M, Benasso M, Rosso R, Sertoli MR, Cavallari M, Scala M, Guenzi M, Siragusa A: Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67: 915–921, 1991

    Google Scholar 

  101. Stupp R, Vokes E: Chemotherapy of head and neck tumors. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD (eds) Comprehensive Management of Head and Neck Tumors. W.B. Saunders Company, Philadelphia. 1999. Vol 1, pp 141–156

    Google Scholar 

  102. Rentschler RE, Wilbur DW, Petti GH, Chonkich GD, Hilliard DA, Camacho ES, Thorpe RB: Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas — a prospective, randomized study. J Clin Oncol 5: 278–285, 1987

    Google Scholar 

  103. Johnson JT, Myers EN, Schramm VL, Mayernik DG, Nolan TA, Sigler BA, Wagner RL: Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck. J Clin Oncol 5: 456–458, 1987

    Google Scholar 

  104. Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46: 175–184, 1998

    Google Scholar 

  105. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295–306, 1998

    Google Scholar 

  106. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl Med Commun 15: 613–627, 1994

    Google Scholar 

  107. De Bree R, Roos JC, Quak JJ, Den Hollander W, Van den Brekel MWM, Van De Wal JE, Snow GB, Van Dongen GAMS: Clinical imaging of head and neck cancer with 99mTc-labeled monoclonal antibody E48 IgG or F(ab′)2. J Nucl Med 35: 775–783, 1994

    Google Scholar 

  108. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Radioimmunoscintigraphy with 99m-Tc-labeled monoclonal antibody U36 and its biodistribution in patients with head and neck cancer. Clin Cancer Res 1, 591–598, 1995

    Google Scholar 

  109. De Bree R, Roos JC, Quak JJ, Den Hollander W, Wilhelm AJ, Van Lingen A, Snow GB, Van Dongen GAMS: Biodistribution and pharmacokinetics of radiolabeled monoclonal antibodies E48 IgG and F(ab′)2 in patients with head and neck cancer. Clin Cancer Res 1: 277–286, 1995

    Google Scholar 

  110. Van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA: High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 80 Suppl: 2360–2370, 1997

    Google Scholar 

  111. Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GB: Progress in radioimmunotherapy of head and neck cancer. Oncology Rep 1: 259–264, 1994

    Google Scholar 

  112. Gerretsen M, Visser GWM, Brakenhoff RH, Van Walsum M, Snow GB, Van Dongen GAMS: Complete ablation of small head and neck cancer xeno-grafts with 186Re-labeled MAb E48 IgG. Cell Bioph 24: 135–142, 1994

    Google Scholar 

  113. Gerretsen M, Visser GWM, van Walsum M, Meijer CJLM, Snow GB, Van Dongen GAMS: 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 53: 3524–3229, 1995

    Google Scholar 

  114. Van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA: Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 77: 13–18, 1998

    Google Scholar 

  115. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1–6, 1995

    Google Scholar 

  116. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221–2232, 1998

    Google Scholar 

  117. Breau RL, Clayman GL: Gene therapy for head and neck cancer. Curr Opin Oncol 8: 227–231, 1996

    Google Scholar 

  118. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373–376, 1996

    Google Scholar 

  119. Heise C, Sampson-Johannes A, Williams A, McCormick F, Vonhoff DD, Kirn DH: Onyx-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3: 639–645, 1997

    Google Scholar 

  120. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med 4: 1068–1072, 1998

    Google Scholar 

  121. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zurhausen H: Replication of onyx-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470–9478, 1998

    Google Scholar 

  122. Rocco JW, Li D, Liggett WH Jr, Duan L, Saunders JK Jr, Sidransky D, O'Malley BW Jr: p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4: 1697–1704, 1998

    Google Scholar 

  123. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech 14: 1574–1578, 1996

    Google Scholar 

  124. Dmitriev I, Krasnykh V, Miller CR, Wang MH, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706–9713, 1998

    Google Scholar 

  125. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD: Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol 17: 449–456, 1989

    Google Scholar 

  126. Licciardello JT, Spitz MR, Hong WK: Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol 17: 467–476, 1989

    Google Scholar 

  127. Schaart LH, Ozsahin M, Zhang GN, Touboul E, De-Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlienger M: Synchronous and metachronous head and neck carcinomas. Cancer 74: 33–38, 1994

    Google Scholar 

  128. Slaughter DP, Southwick HW, Smejkal W: ‘Field cancerisation’ in oral stratified squamous epithelium: Clinical implication of multicentric orgin. Cancer 6: 963–968, 1953

    Google Scholar 

  129. Warren S, Gates O: Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 16: 1358–1414, 1932

    Google Scholar 

  130. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795–801, 1990

    Google Scholar 

  131. Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D: Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56: 2484–2487, 1996

    Google Scholar 

  132. Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, Sidransky D, Jen J, Westra WH: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Nat Cancer Inst 90: 972–977, 1998

    Google Scholar 

  133. Cloos J, Braakhuis BJM, Steen I, Copper MP, de Vries N, Nauta JJP, Snow GB: Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56: 816–819, 1994

    Google Scholar 

  134. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang Z, Tobi H, Braakhuis BJM, Snow GB: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 530–535, 1996.

    Google Scholar 

  135. De Vries N, Van Zandwijk N, Pastorino U: Chemoprevention of second primary tumours in head and neck cancer in Europe: Euroscan. Eur J Cancer 30B: 367–368, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oral-maxillo-facial surgery, Charite University Clinic, Humboldt University Berlin, Campus Virchow Clinic, Berlin, Germany

    Hans J. Gath

  2. Section Tumor Biology, Department of Otolaryngology/Head and Neck surgery, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    Ruud H. Brakenhoff

Authors
  1. Hans J. Gath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruud H. Brakenhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gath, H.J., Brakenhoff, R.H. Minimal Residual Disease in Head and Neck Cancer. Cancer Metastasis Rev 18, 109–126 (1999). https://doi.org/10.1023/A:1006268621730

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006268621730

Search

Navigation